Gene or Genome – Page 20

AstraZeneca and Daiichi Sankyo’s TROP2 ADC Demonstrates Clinically Meaningful Survival Improvement in Phase 3 Lung Cancer Subgroup

11 months ago talkbio0Tagged AstraZeneca, Continuance of life, Daiichi, Datopotamab, Deruxtecan, Improvement, Malignant neoplasm of lung, Nonsquamous Non-Small Cell Lung Cancer, Phase 3 trial, Sankyo, TACSTD2 gene, therapeutic autologous dendritic cells

AstraZeneca, Daiichi Sankyo, TROP2 ADC, Datopotamab Deruxtecan, Lung Cancer, Phase 3 Trial, Survival Improvement, Nonsquamous Non-Small Cell Lung Cancer

ASCO24: Nimbus Unveils Promising Early Data for Next-Generation HPK1 Blocker in IO Therapies

11 months ago talkbio0Tagged ASCO24, Blocker, Clinical Trials, immuno-oncology, Malignant Neoplasms, MAP4K1 gene, Next-Generation IO Therapies, Nimbus

ASCO24, Nimbus, Next-Generation IO Therapies, HPK1 Blocker, Early Data, Cancer Treatment, Immuno-Oncology, Clinical Trials.

Tango Pauses Clinical Trials of Promising Solid Tumor Treatment Due to Liver Toxicity Concerns

11 months ago talkbio0Tagged ARNT gene, aspects of adverse effects, Cancer Research, Clinical Trials, Drug Development, Liver, solid tumor treatment, Toxicity aspects

Tango Therapeutics, solid tumor treatment, clinical trials, liver toxicity, drug development, cancer research, treatment side effects, patient safety.

FDA Greenlights Amgen’s Innovative T Cell Therapy for Aggressive Lung Cancer

11 months ago talkbio0Tagged Aggressive behavior, AMELX gene, amgen, bi-specific, Cancer Therapeutic Procedure, Clinical Trials, Immunotherapy, Malignant neoplasm of lung, Small cell carcinoma of lung, T-Lymphocyte, United States Food and Drug Administration

FDA, Amgen, T cell engager, lung cancer, aggressive, AMG 757, bi-specific T cell engager, small cell lung cancer, immunotherapy, cancer treatment, clinical trials.

Johnson & Johnson Expands into IL-13 and TSLP Market with Strategic Acquisition

11 months ago talkbio0Tagged Acquisition (action), Biological Factors, competition, Drug Industry, expansion, I&I, Inflammatory disorder, Interleukin-13, Johnson and Johnson, Market, strategic, TSLP gene

Johnson & Johnson, I&I acquisition, IL-13, TSLP, competitive market, strategic expansion, pharmaceutical industry, biologics, inflammatory diseases.

ICER Raises Concerns Over Uncertainties in Lykos MDMA Clinical Trials Ahead of FDA Advisory Committee Meeting

11 months ago talkbio0Tagged AdComm, Advisory Committees, Clinical Trials, CREM gene, Lykos ', Midomafetamine, Uncertainty, United States Food and Drug Administration

ICER, Lykos, MDMA, clinical trials, uncertainties, FDA, AdComm, advisory committee meeting

Merck Pauses Phase 3 TIGIT Trial Due to Immune-Mediated Adverse Events

12 months ago talkbio0Tagged Discontinuation (procedure), immune-mediated adverse events, Merck, Phase 3 trial, TIGIT gene

Merck, Phase 3 Trial, TIGIT, Immune-mediated Adverse Events, Discontinuations

Gene or Genome

Gene therapy technique used to restore hearing in congenitally deaf children

12 months ago talkbio0Tagged gene therapy, Hearing Impaired Persons

The gene therapy technique used to restore hearing in congenitally deaf children involves the use of adeno-associated viruses (AAVs) to deliver a functional copy of the gene responsible for producing otoferlin, a protein necessary for the transmission of sound signals from the inner ear to the brain. This gene therapy approach targets children with a […]